For de som frykter at NANO er forlat og på vei til havets bunn uten interesse fra markedet, her er en ganske fin nyansering fra en biotek-ekspert i USA som handler om tidenes sektorfall på 60 % siden februar 2021:
Small companies may offer the most upside, but their low valuations suggest that currently they have small fan-bases, though that can be misleading. As I discussed above, there may be a financing overhang phenomenon keeping a growing number of interested investors on the sidelines, in which case the company may be able to get more capital than the trajectory of its stock price would suggest. Usually CEOs have a sense whether investors are eagerly awaiting an opportunity to participate in a financing. In fact, now is exactly when large biotech specialists have the best opportunity to capitalize what they consider to be high-quality but grossly misunderstood small companies on very attractive terms. We’ve already seen and will no doubt see more of such financings.
Anbefaler å lese siste innlegg fra @h3nk1 delt på tråden Biotekaksjer.
